Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L- proline and L-isoleucyl-L-prolyl-L-proline): IV. Assessment of the repeated-dose toxicological potential of synthesized L-valyl-L-prolyl-L-proline in male and female rats and dogs

International Journal of Toxicology

Volumn 24, Issue SUPPL. 4, 2005, Pages 25-39

  Nakamura, Yasunori ^a   Bando, Izuki ^a   Mennear, John H ^b   Bernard, Bruce K ^c  

^a CALPIS Co Ltd   (Japan)

^b CAMPBELL UNIVERSITY   (United States)

^c GENERAL DYNAMICS   (United States)

Author keywords

Dogs; IPP; Maximum Tolerated Dose; No Observable Effect Level; Rats; Repeated Dose Toxicity; Tripeptide; VPP

Indexed keywords

FOOD ADDITIVE; GELATIN; ISOLEUCYLPROLYLPROLINE; TRIPEPTIDE; UNCLASSIFIED DRUG; VALYLPROLYLPROLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPETITE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOG; DOSE RESPONSE; ELECTROCARDIOGRAPHY; FEMALE; FOOD INTAKE; GLIOSIS; HISTOPATHOLOGY; MALE; MILK; MINERALIZATION; NEUROTOXICITY; NONHUMAN; OPTIC NERVE; TOXICITY TESTING; UTERUS WEIGHT;

ANIMALIA; CANIS FAMILIARIS;

EID: 27544445339     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1080/10915810500259580     Document Type: Article

References (13)

1. Armitage, P. 1955. Test for linear trend in proportions and frequencies. Biometrics 11:375-386.
2. Bernard, B. K., Y. Nakamura, K. Aihara, and J. H. Mennear. 2005a. Studies of the lexicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): IX. Evaluation of the mutagenic potential of synthesized L-valyl-L-prolyl-L-proline in the Salmonella-Escherichia coli/microsome incorporation assay. Int. J. Toxicol. 24(Suppl. 4):107-113.
3. Bernard, B. K., Y. Nakamura, I. Bando, and J. H. Mennear. 2005b. Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): II. Introduction. Int. J. Toxicol. 24(Suppl. 4):5-11.
4. Blom, G. 1958. Statistical estimates and transformed beta variables. New York: John Wiley and Sons.
5. Kurosaki, T., M. Maeno, J. H. Mennear, and B. K. Bernard. 2005. Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): VI. Effects of Lactobacillus helveticus-fermented milk powder on fertility and reproductive performance of rats. Int. J. Toxicol. 24(Suppl. 4):61-89.
6. Maeno, M., S. Mizuno, J. H. Mennear, and B. K. Bernard. 2005a. Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): VIII. Assessment of cytotoxicity and clastogenicity of tripeptides-containing casein hydrolysate and Lactobacillus helveticus-fermented milk powders in Chinese hamster lung cells. Int. J. Toxicol. 24(Suppl. 4):97-105.
7. Maeno, M., Y. Nakamura, J. H. Mennear, and B. K. Bernard. 2005b. Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): III. Single- and/or repeated-dose toxicity of tripeptides-containing Lactobacillus helveticus-fermented milk whey powder and casein hydrolysate in rats. Int. J. Toxicol. 24(Suppl. 4):13-23.
8. Matsuura, K., J. H. Mennear, M. Maeno, and B. K. Bernard. 2005. Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): VII. Micronucleus test of tripeptides- containing casein hydrolysate and Lactobacillus helveticus-fermented milk powders in rats and mice. Int. J. Toxicol. 24(Suppl. 4):91-96.
9. Mizuno, S., J. H. Mennear, K. Matsuura, and B. K. Bernard. 2005. Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): V. A 13-week toxicity study of tripeptides-containing casein hydrolysate in male and female rats. Int. J. Toxicol. 24(Suppl.4):41-59.
10. Selwyn, M. R., and P. P. Gaccione. 1993. Assessing normality and equivariance in small multi-group samples. Commun. Stat. Simul. Comput. 22:61-79.
11. Shirley, E. 1997. An non-parametric equivalent of William's test for contrasting increasing dose levels of a treatment. Biometrics 33:386.
12. Williams, D. A. 1971. A test for difference between treatments means when several dose levels are compared with a zero dose level. Biometrics 27:103.
13. Williams, D. A. 1972. The comparison of several dose levels with a zero dose control. Biometrics 28:519.